Y10S 530/808
Materials and products related to genetic engineering or hybrid or fused cell
Official title: Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
Y10S530/808 (Materials and products related to genetic engineering or hybrid or fused cell) appears on 650 US grants and 158 published applications in this corpus.
Search patents in Y10S- Granted patents
- 650
- Published applications
- 158
- Assignees
- 309
- Inventors
- 1,084
- Latest grant
- 18 Feb 2020
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1980 | 2 | 0 |
| 1981 | 2 | 0 |
| 1982 | 14 | 0 |
| 1983 | 8 | 0 |
| 1984 | 22 | 0 |
| 1985 | 31 | 0 |
| 1986 | 5 | 0 |
| 1987 | 39 | 0 |
| 1988 | 33 | 0 |
| 1989 | 55 | 0 |
| 1990 | 59 | 0 |
| 1991 | 38 | 0 |
| 1992 | 28 | 0 |
| 1993 | 13 | 0 |
| 1994 | 12 | 0 |
| 1995 | 14 | 0 |
| 1996 | 10 | 0 |
| 1997 | 24 | 0 |
| 1998 | 27 | 0 |
| 1999 | 23 | 0 |
| 2000 | 18 | 0 |
| 2001 | 17 | 1 |
| 2002 | 20 | 14 |
| 2003 | 10 | 21 |
| 2004 | 8 | 6 |
| 2005 | 7 | 14 |
| 2006 | 12 | 8 |
| 2007 | 9 | 9 |
| 2008 | 11 | 9 |
| 2009 | 13 | 10 |
| 2010 | 8 | 15 |
| 2011 | 14 | 8 |
| 2012 | 16 | 13 |
| 2013 | 8 | 8 |
| 2014 | 9 | 2 |
| 2015 | 3 | 4 |
| 2016 | 4 | 5 |
| 2017 | 1 | 2 |
| 2018 | 2 | 3 |
| 2019 | 0 | 0 |
| 2020 | 1 | 0 |
| 2021 | 0 | 3 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 1 |
| 2025 | 0 | 1 |
By publication year. Applications have been published since 2001.
Subgroups
Granted patents
Recent patents
- Treating inflammation with IL-17/IL-23 bispecific antibodies18 Feb 2020US 10,562,967 B2ZymoGenetics, Inc.
- Monoclonal antibodies that bind both IL-17A and IL-17F19 Jun 2018US 10,000,563 B2ZymoGenetics, Inc.
- Use of an IL-17/IL-23 bispecific antibody for treating inflammation12 Jun 2018US 9,994,634 B2ZymoGenetics, Inc.
- Compositions and methods for diagnosing and treating cancer11 Apr 2017US 9,617,340 B2OncoMed Pharmaceuticals, Inc.
- Polynucleotides encoding antagonists of IL-17A, IL-17F, and IL-23p1911 Oct 2016US 9,464,134 B2ZymoGenetics, Inc.
- Treatment and Prophylaxis of Amyloidosis28 Aug 2025US 2025/0268999 A1University of Tennessee Research Foundation
- Antigen binding molecules with increased fc receptor binding affinity and effector function12 Sep 2024US 2024/0301079 A1Roche Glycart AG
- Antigen binding molecules with increased fc receptor binding affinity and effector function6 Jul 2023US 2023/0212303 A1Roche Glycart AG
- Monoclonal antibody targeting human tumor stem cells and use thereof20 May 2021US 2021/0147571 A1Suzhou Bojuhua Biomedical Technology Co. Ltd
- Treatment and Prophylaxis of Amyloidosis14 Jan 2021US 2021/0008185 A1University of Tennessee Research Foundation
Most cited
By later US patents
- Recombinant monoclonal antibodies385US 4,474,893 AThe University of Texas System Cancer Center · 1984
- Tumoricidal methotrexate-antibody conjugate378US 4,699,784 ACenter for Molecular Medicine and Immunology · 1987
- Antibody compositions for selectively inhibiting VEGF356US 6,342,219 B12002
- Process for producing biologically functional molecular chimeras329US 4,237,224 AThe Board of Trustees of the Leland Stanford Jr. University · 1980
- Human recombinant interleukin-2 muteins297US 4,518,584 ACetus Corporation · 1985